Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 15/20 | 0.42 |
| ▸ | NPY1R | P25929 | 9/20 | 0.42 |
| ▸ | NPY5R | Q15761 | 8/20 | 0.42 |
| ▸ | NPY2R | P49146 | 5/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | FURIN | P09958 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24419897 | 0.94 | NPY4R (0.43) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL30302903 | 0.93 | NPY4R (0.43) | NPY4RNPY1RNPY5RNPY2RSMN1; SMN2 | |
| SCHEMBL29658786 | 0.91 | FURIN (0.38) | NPY4RNPY1RNPY5RNPY2RFURIN | |
| SCHEMBL30685283 | 0.90 | NPY4R (0.45) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL30658148 | 0.90 | ENPEP (0.42) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL32679342 | 0.90 | NPY4R (0.40) | NPY4RNPY1RNPY5RNPY2RFURIN | |
| SCHEMBL31410686 | 0.88 | KEAP1 (0.41) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL31265325 | 0.88 | NPY4R (0.43) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL9819648 | 0.88 | NPY4R (0.41) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL29697049 | 0.88 | NPY4R (0.41) | NPY4RNPY1RNPY5RNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12496350-B2 | Cyclic peptidyl inhibitors of CAL-PDZ binding domain | OHIO STATE INNOVATION FOUNDATION (US) | 2025-12-16 | — | — | US | disclosed |
| US-20240173423-A1 | CYCLIC PEPTIDYL INHIBITORS OF CAL-PDZ BINDING DOMAIN | OHIO STATE INNOVATION FOUNDATION | 2024-05-30 | — | — | US | disclosed |
| US-11793884-B2 | Cyclic peptidyl inhibitors of CAL-PDZ binding domain | OHIO STATE INNOVATION FOUNDATION (US) | 2023-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11793884-B2 | Cyclic peptidyl inhibitors of CAL-PDZ binding domain | CNBP, CALU, CLSPN | NPY4R 830/4885NPY1R 523/4885NPY5R 1338/4885 |
| US-20240173423-A1 | CYCLIC PEPTIDYL INHIBITORS OF CAL-PDZ BINDING DOMAIN | CNBP, CALU, CLSPN | NPY4R 830/4885NPY1R 523/4885NPY5R 1338/4885 |
| US-12496350-B2 | Cyclic peptidyl inhibitors of CAL-PDZ binding domain | CNBP, CALU, CLSPN | NPY4R 830/4885NPY1R 523/4885NPY5R 1338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.